AC Immune SA

About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in developing precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and certain rare indications. The company aims to address the social and economic imperative created by the growing incidence of these diseases through pioneering science, cutting-edge technology platforms, and a diverse pipeline of clinical and preclinical product candidates.

Products & Services

Morphomer® and SupraAntigen® Platforms:Technology platforms delivering best-in-class small molecules and biologics for diagnostic and therapeutic candidates targeting neurodegenerative diseases.

Active Immunotherapies:Therapeutic candidates focused on preventing Alzheimer's and Parkinson's diseases through early and safe intervention.

Antibodies and Small Molecule Drugs:Part of a broad pipeline integrating diagnostic and therapeutic solutions against validated therapeutic targets for neurodegenerative diseases.

Diagnostic Agents:Tools to enable detection and clearance of pathological proteins underlying neurodegenerative diseases.

ACI-24.060:An anti-amyloid-beta active immunotherapy for Alzheimer's disease, which has received FDA Fast Track Designation.

PI-2620:A Tau PET diagnostic for Alzheimer's disease, currently in Phase 3 study in collaboration with Life Molecular Imaging.

Specialties

Precision Medicine for Neurodegenerative Diseases Active Immunotherapies Antibodies and Small Molecule Drugs Diagnostic Agents for Neurodegeneration Alzheimer's Disease Treatment Parkinson's Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 4000000 MR: - FA: $4 million FAN: 4000000	D: 2026-06-11 FD: 2026-06-11	1 investors
2	RT: Milestone Payment T: - FT: Milestone Payment	A: 27552000 MR: - FA: 24.6 million FAN: 27552000	D: 2024-09-17 FD: 2024-09-17	1 investors
3	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 50100000 MR: - FA: USD 50.1 million FAN: 50100000	D: 2023-12-15 FD: 2023-12-15	4 investors
4	RT: Grant T: - FT: Grant	A: 500000 MR: - FA: more than USD 500,000 FAN: 500000	D: 2023-02-07 FD: 2023-02-07	2 investors

Grant Latest

2026-06-11

$4.0M

1 investor (Pro only)

Milestone Payment 2024-09-17

$27.6M

Underwritten Public Offering 2023-12-15

$50.1M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Andrea Pfeifer

Co-Founder, Chief Executive Officer and Director

C

Christopher Roberts

Chief Financial Officer

P

Piergiorgio Donati

Chief Technical Operations Officer

H

Howard Donovan

Chief Human Resources Officer

M

Mark Danton

EVP, Artificial Intelligence and Information Systems

G

Günther Staffler

EVP, Development

View 30 more team members with Pro

Unlock Full Team Directory

Recent News

AC Immune SA Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised